A Treatment for Paroxysmal Nocturnal Hemoglobinuria Was Accepted for Priority Review
<a href="https://pixabay.com/users/Clker-Free-Vector-Images/">Clker-Free-Vector-Images</a> / Pixabay

A Treatment for Paroxysmal Nocturnal Hemoglobinuria Was Accepted for Priority Review

According to a story from Morningstar, the company Alexion Pharmaceuticals recently announced that the U.S. Food and Drug Administration (FDA) has agreed to review their Biologics Licensing Application for their…

Continue Reading
Recent Study Results Reveal New Possibilities in Treating Paroxysmal Nocturnal Hemoglobinuria (PNH)
PNH causes the immune system to destroy red blood cells. Source: pixabay.com

Recent Study Results Reveal New Possibilities in Treating Paroxysmal Nocturnal Hemoglobinuria (PNH)

On December 11, Alexion Pharmaceuticals, Inc. released dose-ranging data from a recent clinical study involving treatment with ALXN1210, which is an investigational long-acting C5 complement inhibitor meant to treat sufferers…

Continue Reading
Close Menu